


T0:Auto-reply fax 858 720 2555 COMPANY:

Auto-Reply Facsimile Transmission



TO:

Fax Sender at 858 720 2555

Fax Information

Date Received:

1/25/02 6:21:02 PM [Eastern Standard Time]

Total Pages:

5 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 702.04 et seq.

Received
Cover
Page
=====>

01/25/2002 15:18 FAX 858 720 2555 BROBECK SD 001					
FACSIMILE TRANSMISSION <small>Transmission problems: (858) 720-2696</small>					
January 25, 2002					
Brobeck <small>ATTORNEYS AT LAW</small>					
<small>Brobeck, Phleger & Harrison LLP 12390 El Camino Real San Diego, California 92130-2061 PHONE 858.720.2500 FAX 858.720.2555 www.brobeck.com</small>					
PAGES TO FOLLOW COVER 4 USER ID 6348 CMID NUMBER 030727.0027.CON1					
TO					
<small>RECIPIENT</small>	<small>COMPANY</small>	<small>TELEPHONE</small>	<small>FAX</small>		
TC1600-Customer Service (1619)	United States Patent and Trademark Office	800-786-9199	703-872-9305		
FROM					
<small>SENDER</small>	<small>EMAIL</small>	<small>TELEPHONE</small>	<small>FAX</small>		
Janice Crisp	JCrisp@Brobeck.com	(858) 720-2893	(858) 720-2555		
MESSAGE					
<small>Re: U.S. Patent Application Serial No. 09/978,454 Filing Date: October 15, 2001</small>					
<small>P R I V I L E G E D A N D C O N F I D E N T I A L</small>					
<small>All information transmitted hereby is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and mail the original message to us at the above address.</small>					
<small>Received from <858 720 2555> at 1/25/02 6:21:02 PM [Eastern Standard Time]</small>					

FACSIMILE TRANSMISSION

Transmission problems: (858) 720-2696

Brobeck

ATTORNEYS AT LAW

January 25, 2002

Brobeck, Phleger & Harrison LLP
12390 El Camino Real
San Diego, California 92130-2081
PHONE 858.720.2500
FAX 858.720.2555
www.brobeck.com

PAGES TO FOLLOW COVER	4	USER ID	6348	CMID NUMBER	030727.0027.CON1
-----------------------	---	---------	------	-------------	------------------

T O

RECIPIENT	COMPANY	TELEPHONE	FAX
TC1600-Customer Service (1619)	United States Patent and Trademark Office	800-786-9199	703-872-9305

F R O M

SENDER	EMAIL	TELEPHONE	FAX
Janice Crisp	JCrisp@Brobeck.com	(858) 720-2893	(858) 720-2555

M E S S A G E

Re: U.S. Patent Application Serial No. 09/978,454
Filing Date: October 15, 2001

P R I V I L E G E D A N D C O N F I D E N T I A L

All information transmitted hereby is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and mail the original message to us at the above address.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:)
Erion et al.) Group Art Unit: 1619
Serial No.: 09/978,454)
Filed: October 15, 2001)
For: NOVEL PRODRUGS FOR)
PHOSPHORUS-CONTAINING)
COMPOUNDS)

SECOND PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination please amend the above-captioned application as follows:

CERTIFICATE OF TRANSMISSION
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being transmitted via facsimile to the United States Patent and Trademark Office on the date shown below.

JANICE CRISP
Name of Person Transmitting Paper

1-25-02

Date of Transmission

JANICE CRISP
Signature of Person Transmitting Paper

In the Claims:

Please amend Claim 5 to appear as follows:

5. (Amended) The pharmaceutical composition of claim 2, wherein MH is selected from penciclovir, 3TC, ACV, PMPA, araC, ribavirin, fludarabine, and 5-fluoro-2'-deoxyuridine.

Please add the following new claim:

13. (New) The pharmaceutical composition of claim 6 wherein MH is 2'-deoxy-5-¹²⁵I-iodouridine.

REMARKS

Upon entry of this Second Preliminary Amendment, claims 2-13 will be pending. Claim 5 has been amended and new claim 13 has been added. Support for adding fludarabine to claim 5 can be found, for example, at page 39, lines 20 and 41. Support for new claim 13 can be found throughout the specification, for example, at page 42, lines 19-23. Therefore, no new matter has been added by reason of this amendment.

CONCLUSION

In view of the foregoing, Applicants believe that the entire application is in condition for allowance and such action is respectfully requested.

It is believed that no additional fee is due for filing this amendment. If, however, any fee should become due or credit become payable during the pendency of these proceedings, the Examiner is authorized to charge or credit the same to deposit account number 50-1273.

Respectfully submitted,

Erion et al.

Date: January 25, 2002

By: Jessica R. Wolff
Jessica R. Wolff
Reg. No. 37,261

Brobeck, Phleger & Harrison LLP
12390 El Camino Real
San Diego, CA 92130-2081
Direct Dial: (858)720-2696
Facsimile: (858)720-2555

VERSION WITH MARKINGS TO SHOW CHANGES

Claims 5 was amended as follows with the noted changes:

5. (Amended) The pharmaceutical composition of claim 2, wherein MH is selected from penciclovir, 3TC, ACV, PMPA, araC, ribavirin, fludarabine, and 5-fluoro-2'-deoxyuridine.

*** TX REPORT ***

TRANSMISSION OK

TX/RX NO	1802
CONNECTION TEL	30727#0027#17038729305p#
CONNECTION ID	
ST. TIME	01/25 15:18
USAGE T	01 '22
PGS. SENT	5
RESULT	OK

FACSIMILE TRANSMISSION

Transmission problems: (858) 720-2696

Brobeck

ATTORNEYS AT LAW

January 25, 2002

Brobeck, Phleger & Harrison LLP
 12390 El Camino Real
 San Diego, California 92130-2081
 PHONE 858.720.2500
 FAX 858.720.2555
www.brobeck.com

PAGES TO FOLLOW COVER	4	USER ID	6348	CMID NUMBER	030727.0027.CON1
-----------------------	---	---------	------	-------------	------------------

TO

RECIPIENT	COMPANY	TELEPHONE	FAX
TC1600-Customer Service (1619)	United States Patent and Trademark Office	800-786-9199	703-872-9305

FROM

SENDER	EMAIL	TELEPHONE	FAX
Janice Crisp	JCrisp@Brobeck.com	(858) 720-2893	(858) 720-2555

MESSAGE

Re: U.S. Patent Application Serial No. 09/978,454
 Filing Date: October 15, 2001